# iScience Interventional

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iscience-interventional

- Industry: Medical Devices & Equipment
- Headquarters: Menlo Park, US
- Website: www.iscienceinterventional.com
- Total disclosed funding: $74M
- Latest round: Series G (Jan 30, 2012)
- Investors on record: 10

## About

iScience Interventional Inc. is a company that develops innovative medical technologies specifically for interventional ophthalmology, focusing on improving patient outcomes through advanced treatment devices for ocular conditions.Founded in 1999 and headquartered in Menlo Park, US, iScience Interventional specializes in medical devices for treating retinal diseases. The company has completed 12 deals, with its most recent deal occurring on January 20, 2014. It raised a total of USD 2.76 mn, including USD 5.00 mn in its latest funding round, Venture Debt, led by Square 1 Bank.iScience Interventional specializes in developing advanced medical technologies aimed at enhancing patient outcomes in the field of interventional ophthalmology. Their core product offerings include innovative devices designed for the treatment of various ocular conditions, specifically targeting the management of retinal diseases. These products are engineered to facilitate procedures that optimize vision restoration and improve the quality of life for patients suffering from such ailments. The company's solutions are utilized by healthcare professionals in hospitals and outpatient settings, serving a diverse client base that includes ophthalmologists, surgeons, and healthcare institutions across North America, Europe, and Asia. iScience Interventional is committed to delivering technologies that address significant clinical needs, with their products being pivotal in the treatment regimens for patients worldwide.iScience Interventional generates revenue primarily through direct sales of its proprietary medical devices to healthcare facilities and practitioners. Transactions typically involve the sale of flagship products through established distribution channels, ensuring accessibility to medical professionals. The pricing structure reflects the advanced technology and clinical efficacy of their offerings. Partnerships with healthcare organizations and participation in medical supply agreements further bolster their revenue model, enhancing market penetration. The company’s revenue streams are supported by a commitment to ongoing innovation, ensuring that their products remain integral to modern ophthalmological practices.iScience Interventional is focused on expanding its market reach and product offerings. Following its recent acquisition by Ellex Medical Lasers Limited in January 2014, the company is expected to leverage this partnership to enhance its product development efforts. Plans include launching new medical devices targeting additional ocular conditions by 2025, with a focus on entering emerging markets in Asia and South America to facilitate broader access to its technologies. The funds from the latest round of financing are anticipated to support these initiatives, enabling the company to invest in research and development as well as market entry strategies.

## Funding rounds

- Series G, Jan 30, 2012, $2.8M — Prism Venture Management, Three Arch Partners, Affinity Capital Management, De Novo Ventures, Johnson & Johnson Innovation
- Series G, Aug 16, 2011, $3M — Prism Venture Management, Three Arch Partners, Johnson & Johnson Innovation
- Series F, May 5, 2009, $21M — Prism Venture Management, Three Arch Partners, Affinity Capital Management, De Novo Ventures, Johnson & Johnson Innovation, L Capital Partners, Asset Management Ventures, CHV Capital
- Series E, Apr 23, 2009, $2M — Johnson & Johnson Innovation, Affinity Ventures, L Capital Partners, CHV Capital
- Series E, Mar 28, 2007, $20M — Prism Venture Management, Three Arch Partners, De Novo Ventures
- Series D, Apr 20, 2006, $4M — Pacific Horizon Ventures, Prism Venture Management, Three Arch Partners, De Novo Ventures
- Series C, Apr 2, 2005, $15M — Pacific Horizon Ventures, Prism Venture Management, Three Arch Partners, De Novo Ventures, Asset Management Ventures
- Series B, Apr 20, 2003, $7M — Pacific Horizon Ventures, Prism Venture Management, De Novo Ventures, Asset Management Ventures

## Investors

- Pacific Horizon Ventures (https://capitalatlas.ai/funds/pacific-horizon-ventures) — Series B, Series C, Series D
- Prism Venture Management (https://capitalatlas.ai/funds/prism-venture-management) — Series B, Series C, Series D, Series E, Series F, Series G
- De Novo Ventures (https://capitalatlas.ai/funds/de-novo-ventures) — Series B, Series C, Series D, Series E, Series F, Series G
- Asset Management Ventures (https://capitalatlas.ai/funds/asset-management-ventures) — Series B, Series C, Series F
- Three Arch Partners (https://capitalatlas.ai/funds/three-arch-partners) — Series C, Series D, Series E, Series F, Series G
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series E, Series F, Series G
- Affinity Ventures — Series E
- L Capital Partners (https://capitalatlas.ai/funds/l-capital-partners) — Series E, Series F
- CHV Capital (https://capitalatlas.ai/funds/chv-capital) — Series E, Series F
- Affinity Capital Management (https://capitalatlas.ai/funds/affinity-capital-management) — Series F, Series G